How can PSC progression be predicted?

Predicting the course of primary sclerosing cholangitis (PSC) is a major clinical challenge because the disease varies significantly between individuals. Some people may develop severe liver damage, while others face an increased risk of bile duct cancer (CCA), and others face barely any disease progression at all. Researchers are urgently seeking new, non-invasive tools, known as biomarkers, that can provide a clearer and more timely prognosis than current methods. Dr Nouairia’s study was designed to use advanced data analysis to uncover new biological clues.

What did the research team analyse?

The study analysed blood samples from 33 people with and without PSC, measuring three specific types of circulating molecules: microRNAs, proteins, and metabolites. By applying advanced data analysis and machine-learning methods, the research team has successfully identified distinct molecular "signatures" linked to different presentations, or phenotypes, of the disease. This approach allows for a deeper understanding of the subtle biological differences in a condition known for its varied progression.

What are the key findings?

The results represent a crucial step towards developing diagnostic tools that could ultimately help predict disease progression and identify individuals at a higher risk of complications.

Key findings include:

• Each PSC phenotype has its own unique set of molecules that may serve as future biomarkers for disease progression and risk prediction of CCA.
• The machine learning approach could pick up subtle molecular differences between PSC with and without inflammatory bowel disease (IBD), even though they appear very similar biologically.
• Severe PSC and PSC that progresses to CCA were found to share few molecular features, suggesting possible distinct early markers for cancer risk.

What is the impact for people with PSC?

These promising findings move us closer to a future of more personalised follow-up for people living with PSC. If blood-based molecules can reliably predict who is at higher risk of cancer or severe progression, healthcare professionals could tailor monitoring and treatment strategies more effectively. PSC Support is proud to have funded this work, which directly aligns with our mission to unlock understanding and accelerate the development of effective treatments for the PSC community.